About the Authors
- Kristina Hacker
-
Affiliation Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Renke Maas
-
Affiliation Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Johannes Kornhuber
-
Affiliation Department of Psychiatry and Psychotherapy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Martin F. Fromm
-
* E-mail: Martin.Fromm@fau.de
Affiliation Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
- Oliver Zolk
-
Affiliations Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, Institute of Pharmacology of Natural Products & Clinical Pharmacology, Ulm University, Ulm, Germany
Competing Interests
M.F.F. received personal compensation for expert testimony from Boehringer Ingelheim and payments for lectures from Bayer-Schering Pharma, Boehringer Ingelheim AG, Janssen-Cilag and Sanofi-Aventis Deutschland GmbH. His institution received compensation for commissioned research of his group from Merck KGaA and from Sanofi-Aventis Deutschland GmbH and for supply for in vitro studies from Gilead. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. The remaining authors (K.H., R.M., J.K., O.Z.) declare no conflicts of interest.
Author Contributions
Conceived and designed the experiments: KH RM JK MFF OZ. Performed the experiments: KH OZ. Analyzed the data: KH OZ. Contributed reagents/materials/analysis tools: JK RM MFF OZ. Wrote the paper: KH MFF OZ.